1.
Dmytrenko IV, Minchenko ZM, Fedorenko VV, Dyagil IS. SIGNIFICANCE OF ADDITIONAL CHROMOSOMAL ABNORMALITIES FOR THE OUTCOMES AFTER THE SECOND LINE NILOTINIB THERAPY IN THE CHRONIC MYELOID LEUKEMIA PATIENTS. IJMMR [Internet]. 2019Jul.11 [cited 2020Apr.1];5(1):33-9. Available from: https://ojs.tdmu.edu.ua/index.php/ijmr/article/view/10305